High-affinity antibodies in a new immunoassay for plasma tissue factor: reduction in apparent intra-individual variation
-
Roy F. M. van der Putten
Abstract
Tissue factor, the main initiator of blood coagulation, is shed into plasma by blood cells and endothelium. While studying such circulating plasma tissue factor with a commercially available immunoassay, we found unsatisfactory results and therefore developed a new and highly sensitive enzyme-linked immunosorbent assay (ELISA). High-affinity monoclonal antibodies raised against recombinant soluble tissue factor were used and the new assay had a detection limit of 40fmol/L, approximately six-fold lower than existing assays. Normal ranges in 20 healthy donors were established in serum and in citrated EDTA and heparinized plasma. Tissue factor was also measured in three successive plasma samples from 43 patients with type 2 diabetes mellitus. In citrated plasma from healthy donors, tissue factor concentrations were 2.5 (1.0–9.3) pmol/L (median with range) and were not significantly different in diabetics. With a commercially available immunoassay, seven plasma samples were below the detection limit. Use of the new assay reduced intra-individual variation in diabetics from 49% to 14% and we conclude that high-affinity antibodies may markedly improve immunoassay performance.
References
1. Nemerson Y. Tissue factor: then and now. Thromb Haemost 1995; 74:180–4.10.1055/s-0038-1642673Suche in Google Scholar
2. Morrissey JH. Tissue factor modulation of factor VIIa activity: use in measuring trace concentrations of factor VIIa in plasma. Thromb Haemost 1995; 74:185–8.10.1055/s-0038-1642674Suche in Google Scholar
3. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96:2311–5.10.1073/pnas.96.5.2311Suche in Google Scholar
4. Ryan J, Brett J, Tijburg P, Bach RR, Kisiel W, Stern D. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood 1992; 80:966–74.10.1182/blood.V80.4.966.966Suche in Google Scholar
5. Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, et al. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997; 100:2276–85.10.1172/JCI119765Suche in Google Scholar
6. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99:348–53.10.1161/01.CIR.99.3.348Suche in Google Scholar
7. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9:458–62.10.1038/nm841Suche in Google Scholar
8. Suefuji H, Ogawa H, Yasue H, Kaikita K, Soejima H, Motoyama T, et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134:253–9.10.1016/S0002-8703(97)70132-7Suche in Google Scholar
9. Albrecht S, Kotzsch M, Siegert G, Luther T, Grossmann H, Grosser M, et al. Detection of circulating tissue factor and factor VII in a normal population. Thromb Haemost 1996; 75:772–7.10.1055/s-0038-1650365Suche in Google Scholar
10. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998; 79:495–9.10.1055/s-0037-1614932Suche in Google Scholar
11. Maly M, Vojacek J, Hrabos V, Kvasnicka J, Salaj P, Durdil V. Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome. Physiol Res 2003; 52:719–28.Suche in Google Scholar
12. Sommeijer DW, MacGillavry MR, Meijers JC, Van Zanten AP, Reitsma PH, Ten Cate H. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care 2004; 27:468–73.10.2337/diacare.27.2.468Suche in Google Scholar
13. Rezaie AR, Fiore MM, Neuenschwander PF, Esmon CT, Morrissey JH. Expression and purification of a soluble tissue factor fusion protein with an epitope for an unusual calcium-dependent antibody. Protein Expr Purif 1992; 3:453–60.10.1016/1046-5928(92)90062-2Suche in Google Scholar
14. Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999; 45:942–56.10.1093/clinchem/45.7.942Suche in Google Scholar
15. Van Landeghem AA, Soons JB, Wever RA, Mul-Steinbusch MW, Antonissen-Zijda T. Purification and determination of the modifying protein responsible for the post-synthetic modification of creatine kinase (EC 2.7.3.2) and enolase (EC 4.2.1.11). Clin Chim Acta 1985; 153:217–24.10.1016/0009-8981(85)90355-9Suche in Google Scholar
16. Diris JH, Hackeng CM, Kooman JP, Pinto YM, Hermens WTh, van Dieijen-Visser M. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation 2004; 109:23–5.10.1161/01.CIR.0000109483.45211.8FSuche in Google Scholar PubMed
17. van der Putten RF, te Velthuis H, de Zwaan C, Aarden LA, Glatz JF, Hermens WT. State and diagnostic value of plasma tissue factor in early hospitalised patients with chest pain. Br J Haematol 2005; 131:91–9.10.1111/j.1365-2141.2005.05722.xSuche in Google Scholar PubMed
18. Hermens WT, Benes M, Richter R, Speijer H. Effects of flow on solute exchange between fluids and supported biosurfaces. Biotechnol Appl Biochem 2004; 39:277–84.10.1042/BA20030113Suche in Google Scholar PubMed
19. Lim HS, Blann AD, Lip GYH. Soluble CD-40 ligand, soluble P-selectin, interleukin-6 and tissue factor in diabetes mellitus. Circulation 2004; 109:2524–8.10.1161/01.CIR.0000129773.70647.94Suche in Google Scholar PubMed
©2005 by Walter de Gruyter Berlin New York
Artikel in diesem Heft
- Contents Volume 43, 2005
- Author Index
- Subject Index
- ProteinChips: the essential tools for proteomic biomarker discovery and future clinical diagnostics
- Protein profiling as a diagnostic tool in clinical chemistry: a review
- Protein biochip systems for the clinical laboratory
- Automation of biochip array technology for quality results
- SELDI-TOF-MS proteomics of breast cancer
- Protein microarrays for the diagnosis of allergic diseases: state-of-the-art and future development
- Separation of human serum proteins using the Beckman-Coulter PF2D™ system: analysis of ion exchange-based first dimension chromatography
- Rapid, accurate genotyping of alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 based on the use of denaturing HPLC
- APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals
- Simple PCR heteroduplex, SSCP mutation screening methods for the detection of novel catalase mutations in Hungarian patients with type 2 diabetes mellitus
- Glycogen phosphorylase BB in acute coronary syndromes
- Alteration in serum leptin correlates with alterations in serum N-telopeptide of collagen type I and serum osteocalcin during the progression of osteoporosis in ovariectomized rats
- Glycemic control in diabetes in three Danish counties
- Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells
- Buprenorphine detection in biological samples
- The effect of thyroid antibody positivity on reference intervals for thyroid stimulating hormone (TSH) and free thyroxine (FT4) in an aged population
- High-affinity antibodies in a new immunoassay for plasma tissue factor: reduction in apparent intra-individual variation
- Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex® Multiplex technology
- Sensitive immunoassays for the autoantibodies reacting against citrullinated carboxy-terminal telopeptides of type I and type II collagens in patients with rheumatoid arthritis
- Acknowledgement
Artikel in diesem Heft
- Contents Volume 43, 2005
- Author Index
- Subject Index
- ProteinChips: the essential tools for proteomic biomarker discovery and future clinical diagnostics
- Protein profiling as a diagnostic tool in clinical chemistry: a review
- Protein biochip systems for the clinical laboratory
- Automation of biochip array technology for quality results
- SELDI-TOF-MS proteomics of breast cancer
- Protein microarrays for the diagnosis of allergic diseases: state-of-the-art and future development
- Separation of human serum proteins using the Beckman-Coulter PF2D™ system: analysis of ion exchange-based first dimension chromatography
- Rapid, accurate genotyping of alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 based on the use of denaturing HPLC
- APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals
- Simple PCR heteroduplex, SSCP mutation screening methods for the detection of novel catalase mutations in Hungarian patients with type 2 diabetes mellitus
- Glycogen phosphorylase BB in acute coronary syndromes
- Alteration in serum leptin correlates with alterations in serum N-telopeptide of collagen type I and serum osteocalcin during the progression of osteoporosis in ovariectomized rats
- Glycemic control in diabetes in three Danish counties
- Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells
- Buprenorphine detection in biological samples
- The effect of thyroid antibody positivity on reference intervals for thyroid stimulating hormone (TSH) and free thyroxine (FT4) in an aged population
- High-affinity antibodies in a new immunoassay for plasma tissue factor: reduction in apparent intra-individual variation
- Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex® Multiplex technology
- Sensitive immunoassays for the autoantibodies reacting against citrullinated carboxy-terminal telopeptides of type I and type II collagens in patients with rheumatoid arthritis
- Acknowledgement
